Treatment of Non-COVID-19 Acute Respiratory Distress Syndrome: A Phase 2 Study of the Efficacy and Safety of Intravenous Allogeneic Adipose-Derived Mesenchymal Stem Cells
Latest Information Update: 29 Sep 2021
At a glance
- Drugs PSC-04 (Primary)
- Indications Adult respiratory distress syndrome
- Focus Therapeutic Use
- Sponsors Sorrento Therapeutics
- 17 Sep 2021 Status changed from not yet recruiting to withdrawn prior to enrolment because it is replaced by a different protocol.
- 10 Jun 2021 New trial record